Objective: To explore the gut-brain axis by examining gut hormone levels and cognitive test scores in women with (HIV+) and without (HIV-) HIV infection.
Design/methods: Participants included 356 women (248 HIV+, 108 at risk HIV-) in the Brooklyn Women's Interagency HIV Study (WIHS) with measured levels of ghrelin, amylin and gastric inhibitory peptide (GIP), also known as glucose-dependent insulinotropic polypeptide. Cross-sectional analyses using linear regression models estimated the relationship between gut hormones and Trails A, Trails B, Stroop interference time, Stroop word recall, Stroop color naming and reading, and Symbol Digit Modalities Test (SDMT) with consideration for age, HIV infection status, Wide Range Achievement Test score (WRAT), CD4 count, insulin resistance, drug use, and race/ethnicity.
Results: Among women at mid-life with chronic (at least 10 years) HIV infection or among those at risk, ghrelin, amylin and GIP were differentially related to cognitive test performance by cognitive domain. Better performance on cognitive tests was generally associated with higher ghrelin, amylin and GIP levels. However, the strength of association varied, as did significance level by HIV status.
Conclusion: Previous analyses in WIHS participants have suggested that higher BMI, waist, and WHR are associated with better cognitive function among women at mid-life with HIV infection. This study indicates that higher gut hormone levels are also associated with better cognition. Gut hormones may provide additional mechanistic insights regarding the association between obesity and Type 2 diabetes and cognition in middle-aged HIV+ and at risk HIV- women. In addition, measuring these hormones longitudinally would add to the understanding of mechanisms of actions of these hormones and their use as potential clinical tools for early identification and intervention on cognitive decline in this vulnerable population.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5497768 | PMC |
| http://dx.doi.org/10.4172/2155-9562.1000413 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Investigating the Preventive Effects of Oral Consumption of Dactylorhiza Maculate (Salep) Hydro-alcoholic Extract on Appetite and Body Weight in Male Rats.
Arch Razi Inst
April 2024
Student Research Committee, Jahrom University of Medical Sciences, Jahrom, Iran.
Obesity is the result of positive energy balance in which various hormones and neurotransmitters are involved. Using Dietary supplements is a common and popular method to lose weight. Medicinal plants with specific effects on metabolizing enzymes, blocking adipogenesis, and improving energy metabolism can be a suitable alternative to these supplements.
View Article and Find Full Text PDFEnteropancreatic hormone changes in caloric-restricted diet interventions associate with post-intervention weight maintenance.
Clin Nutr
December 2024
Department of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China; Shanghai National Clinical Research Center for Metabolic Diseases, Key Laboratory for Endocrine and Metabolic Diseases of the National Health Commission of the PR China, Shanghai Key Laboratory for Endocrine Tumor, State Key Laboratory of Medical Genomics, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. Electronic address:
Article Synopsis
- The study examined how changes in enteropancreatic hormones affect weight maintenance after a calorie-restricted diet in individuals with overweight/obesity and prediabetes.
- Participants were assigned to one of three diets (Control, Traditional Jiangnan, Mediterranean) with a 25% calorie reduction, and hormone levels were measured at three intervals: 0, 3, and 6 months.
- Results showed consistent hormonal changes across all diets; decreases in appetite-suppressing hormones (like GLP-1) and increases in appetite-promoting hormone (ghrelin) were linked to greater weight gain post-intervention, suggesting that hormonal changes can predict long-term weight control.
Novel Pharmaceuticals in Appetite Regulation: Exploring emerging gut peptides and their pharmacological prospects.
Pharmacol Res Perspect
August 2024
Department of Internal Medicine, School of Medicine University of Zagreb, Zagreb, Croatia.
Obesity, a global health challenge, necessitates innovative approaches for effective management. Targeting gut peptides in the development of anti-obesity pharmaceuticals has already demonstrated significant efficacy. Ghrelin, peptide YY (PYY), cholecystokinin (CCK), and amylin are crucial in appetite regulation offering promising targets for pharmacological interventions in obesity treatment using both peptide-based and small molecule-based pharmaceuticals.
View Article and Find Full Text PDFExploring the Role of Metabolic Hormones in Amyotrophic Lateral Sclerosis.
Int J Mol Sci
May 2024
Department of Neurology, University of Medicine, Pharmacy, Science and Technology of Târgu Mureș 'George Emil Palade', 540142 Târgu Mureș, Romania.
Amyotrophic lateral sclerosis (ALS) is a devastating neurodegenerative disease characterized by progressive loss of motor neurons. Emerging evidence suggests a potential link between metabolic dysregulation and ALS pathogenesis. This study aimed to investigate the relationship between metabolic hormones and disease progression in ALS patients.
View Article and Find Full Text PDFA long-acting LEAP2 analog reduces hepatic steatosis and inflammation and causes marked weight loss in mice.
Mol Metab
June 2024
Center for Hypothalamic Research, Department of Internal Medicine, UT Southwestern Medical Center, 5323 Harry Hines Blvd., Dallas, TX 75390-9077, USA; Division of Endocrinology, Department of Internal Medicine, UT Southwestern Medical Center, USA; Department of Psychiatry, UT Southwestern Medical Center, 5323 Harry Hines Blvd., Dallas, TX 75390, USA. Electronic address:
Objective: The number of individuals affected by metabolic dysfunction associated fatty liver disease [1] is on the rise, yet hormonal contributors to the condition remain incompletely described and only a single FDA-approved treatment is available. Some studies suggest that the hormones ghrelin and LEAP2, which act as agonist and antagonist/inverse agonist, respectively, for the G protein coupled receptor GHSR, may influence the development of MAFLD. For instance, ghrelin increases hepatic fat whereas synthetic GHSR antagonists do the opposite.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!